Engineered immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT05805371
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new treatment for men with a tough-to-treat form of prostate cancer that has spread and no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells that have a specific marker called PSCA. Some participants will also receive radiation therapy. The main goals are to check safety, find the best dose, and see if the treatment can shrink tumors or lower PSA levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PSCA-targeting CAR-T cells (a type of immune cell therapy made from the patient's own blood)
- What this could lead to
- If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is a very early phase 1 trial with only 21 participants, so safety and dosing are still being figured out. CAR-T cell therapy can cause serious side effects like cytokine release syndrome and nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread